Nilotinib therapy after resistance to imatinib
In this article we present the case of a 43-year-old man with chronic myeloid leukemia (CML) successfully treated with nilotinib. At presentation we started him on imatinib at standard dose of 400 mg/day but after 36 months of treatment the patient didn’t achieve a molecular response. We switched hi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SEEd
2015-10-01
|
| Series: | Clinical Management Issues |
| Subjects: | |
| Online Access: | https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1137 |